In conclusion, serum and urine IP-10, sGalectin-9, and uSIGLEC-1 seem to be promising biomarkers reflecting global disease activity in patients with SLE although they do not outperform serum C3 and C4. The gene discussed is C3; the disease is systemic lupus erythematosus.